Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Novo Nordisk A/S

NVO ✓ COMPLIANTFree checks used up today ☆ Track — members

NYSE · Healthcare · Pharmaceuticals ·

USA Large Cap Analyst: HOLD

Last Close

$41.09

▲ +0.96%

Market Cap $181.87B · Vol 1.56M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

10.87

FWD: 11.86

Market Cap

$181.87B

Large Cap

Div Yield

4.29%

Semi-annual dividend

EPS Growth

-2.99%

YoY

RSI (14)

58.52

Momentum

Beta

0.71

vs Market

52W High

$64.16

35.96% below

52W Low

$35.13

16.97% above

Volume

1.56M

Avg 1.69M

P/B

7.41

Price-to-book

ROE

60.70%

Return on equity

Free Float

99.99%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Novo Nordisk A/S (NVO) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NVO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.58%

+6.34%

-12.89%

-11.44%

YTD

-19.24%

-16.40%

-59.39%

-27.54%

Financials & Valuation

TTM · Annual

Total Revenue	$48.60B
Net Income	$16.11B
Revenue Growth (YoY)	+3.80%
Gross Margin	82.51%
Operating Margin	46.26%
Net Profit Margin	33.14%
ROE	60.70%
ROA · ROIC	25.88% · 37.46%

P/E Ratio	10.87
Forward P/E (FY1)	11.86
PEG Ratio	2.42
P/S	4.85
P/B	7.41
P/FCF	51.66
EPS Growth	-2.99%
Outstanding Shares	3.39B

Technical Indicators

50-Day SMA	$40.33
200-Day SMA	$43.37
RSI (14)	58.52
Beta	0.71
52-Week High	$64.16
52-Week Low	$35.13

Volume Today	1.56M
Avg Daily Volume (30D)	1.69M
Relative Volume	0.92x
Volatility (10D)	39.02
Volatility (30D)	27.95
Free Float	99.99%

Analyst Consensus

HOLD

Current Price $41.09

Mean Target $48.52

52W Low$35.13 52W High$64.16

Current

Target

$35.13 $64.16

Current Analyst target

+18.09% upside potential · 22 analysts

Identifiers

ExchangeNYSE

FIGIBBG001S5TSK0

ISINUS6701002056

CountryDenmark

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company +0.35% JNJ Johnson & Johnson -0.13% ABBV AbbVie Inc. +0.37% NVS Novartis AG -1.80% NOVN.S Novartis AG -1.29%

Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.